一个血液查测试痴呆症与勒维体的初级保健的血液查测试
Melissa Petersen1,2, Tanis J Ferman3, Fan Zhang1,2
1Department of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.
概括
一项新的血液测试可以准确检测患有莱维体痴呆症 (DLB),将其与帕金森病 (PD) 和阿尔茨海默病 (AD) 区分开来. 这种蛋白质性查方法在初级保健机构的早期检测方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 蛋白质组学是指蛋白质组学.
背景情况:
- 患有勒维体痴呆症 (DLB) 的诊断可能具有挑战性.
- 准确的早期检测对于患者的管理和护理至关重要.
- 现有的诊断方法可能是侵入性的或耗时的.
研究的目的:
- 为了交叉验证以前开发的痴呆症与勒维体 (DLB) 的血液测试.
- 评估蛋白质基因特征的诊断准确性,以区分DLB与其他神经退行性疾病.
- 评估基于血液的测试对初级保健实施的潜力.
主要方法:
- 分析了来自428个人的血样本:DLB (n=89),没有痴呆症的帕金森病 (PD,n=126),阿尔茨海默病 (AD,n=108) 和正常对照 (NC,n=105).
- 采用蛋白质组特征结合人口统计数据 (年龄,性别,教育) 进行分析.
- 曲线下的就业面积 (AUC) 用于测量诊断歧视.
主要成果:
- 蛋白质组特征区分了DLB和PD与NC,其AUC为0.96.
- DLB与PD有区别,其AUC为0.92.
- 该测试将DLB,PD和AD与NC区分开来 (AUC=0.95),DLB与AD区分开来 (AUC=0.92).
结论:
- 这项研究提供了进一步的证据,证明了多层次的基于血液的蛋白质基查方法对DLB检测的有用性.
- 这种血液检查可以有效地区分DLB与正常控制,帕金森病和阿尔茨海默病.
- 结果表明,这种测试可以在初级保健中实施,以帮助DLB转诊过程.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.对生物标志物进行查.血液中的生物标志物痴呆症与利维体的痴呆症.检测 检测 检测 检测 检测诊断的准确性 诊断的准确性帕金森病是帕金森氏症的一种疾病.蛋白质组学是指蛋白质组学.更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.0K
相关概念视频
Dementia
167
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
167
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
